HUMAN B-LYMPHOCYTE TUMOR XENOGRAFTS IN SCID MICE

SCID 小鼠中的人 B 淋巴细胞肿瘤异种移植物

• 批准号: 3493076
• 负责人: PHILLIP R MORROW
• 金额: $ 5万
• 依托单位: AVANIR PHARMACEUTICALS
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-09-01 至 1992-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3493076
• 关键词: B lymphocyte; antineoplastics; bone marrow transplantation; combination chemotherapy; disease /disorder model; evaluation /testing; host neoplasm interaction; human tissue; immunofluorescence technique; lymphoma; model design /development; monoclonal antibody; natural killer cells; nonhuman therapy evaluation; severe combined immunodeficiency; xenotransplantation

The long term objective of this proposal is to establish reliable human tumor xenograft systems which will be used in the treatment of non- Hodgkin's lymphoma as well as other cancers. Commercial applications which would derive from such systems include: (i) improved screening of compounds for anti-tumor activities; (ii) evaluation of new cancer treatment modalities; (iii) optimizing combination therapies; and (iv) use in developing customized therapies to fit the individual patient. The specific aims of this Phase 1 proposal are to evaluate several parameters which are relevant to optimizing the ability of either human B-cell lines of primary tumor tissue (mainly non-Hodgkin's lymphomas) to become established and usable in SCID mice. Specifically, we propose to: (i) optimize the method of administering human B-cell lines are primary tumor cells to SCID mice; (ii) evaluate the ability of different lymphoma types and/or stages to engraft SCID mice; and (iii) manipulate the SCID mouse host to determine both the effect of the murine background genotypes as well as natural killer (NK) cell function on the ability of human tumor xenografts to become established in SCID mice.

本提案的长期目标是建立可靠的人力资源， 肿瘤异种移植系统，其将用于治疗非- 霍奇金淋巴瘤以及其他癌症。 商业应用 这些系统将产生的影响包括：（一）改进对 用于抗肿瘤活性的化合物;（ii）新癌症的评估 治疗方式;（iii）优化组合疗法;和（iv） 用于开发定制疗法以适应个体患者。 第一阶段提案的具体目标是评估几个 这些参数与优化人类的能力相关， 原发性肿瘤组织（主要是非霍奇金淋巴瘤）的B细胞系， 在SCID小鼠中建立并使用。 具体而言，我们建议：（一）优化管理方法 人B细胞系是SCID小鼠的原代肿瘤细胞;（ii）评价 不同淋巴瘤类型和/或分期移植SCID的能力 小鼠;和（iii）操纵SCID小鼠宿主以确定两种免疫应答。 小鼠背景基因型以及自然杀伤细胞（NK） 细胞功能对人类肿瘤异种移植物成为 在SCID小鼠中建立。